全文获取类型
收费全文 | 65篇 |
免费 | 8篇 |
专业分类
基础医学 | 8篇 |
临床医学 | 20篇 |
内科学 | 7篇 |
外科学 | 6篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 2篇 |
眼科学 | 2篇 |
药学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2019年 | 2篇 |
2017年 | 2篇 |
2015年 | 4篇 |
2014年 | 2篇 |
2012年 | 2篇 |
2011年 | 11篇 |
2010年 | 2篇 |
2009年 | 1篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2005年 | 7篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 7篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1982年 | 1篇 |
排序方式: 共有73条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Vogel C Cobleigh MA Tripathy D Gutheil JC Harris LN Fehrenbacher L Slamon DJ Murphy M Novotny WF Burchmore M Shak S Stewart SJ;Genentech H study investigators 《European journal of cancer (Oxford, England : 1990)》2001,37(Z1):S25-S29
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression. 相似文献
5.
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. 总被引:16,自引:2,他引:14
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S Shak D J Capon R Hellmiss S A Marsters C L Baker 《Proceedings of the National Academy of Sciences of the United States of America》1990,87(23):9188-9192
Respiratory distress and progressive lung destruction in cystic fibrosis can be attributed to bacterial persistence and the accumulation of viscous purulent secretions in the airways. More than 30 yr ago it was suggested that the large amounts of DNA in purulent secretions contribute to its viscosity and that bovine pancreatic DNase I could reduce the viscosity. To evaluate the potential clinical utility of recombinant human DNase I (rhDNase) in the treatment of cystic fibrosis, we have cloned, sequenced, and expressed rhDNase. Catalytic amounts of rhDNase greatly reduce the viscosity of purulent cystic fibrosis sputum, transforming it within minutes from a nonflowing viscous gel to a flowing liquid. The reduction in viscosity is associated with a decrease in size of DNA in the sputum. Inhalation of a rhDNase aerosol may be a simple direct approach that will help individuals with cystic fibrosis and other patients with pneumonia or bronchitis to clear their airways of purulent secretions. 相似文献
6.
Mina L Soule SE Badve S Baehner FL Baker J Cronin M Watson D Liu ML Sledge GW Shak S Miller KD 《Breast cancer research and treatment》2007,103(2):197-208
Purpose Primary chemotherapy provides an ideal opportunity to correlate gene expression with response to treatment. We used paraffin-embedded
core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy.
Patients and Methods Patients with newly diagnosed stage II or III breast cancer were treated with sequential doxorubicin 75 mg/M2 q2 wks × 3 and
docetaxel 40 mg/M2 weekly × 6; treatment order was randomly assigned. Pretreatment core biopsy samples were interrogated for
genes that might correlate with pathologic complete response (pCR). In addition to the individual genes, the correlation of
the Oncotype DX Recurrence Score with pCR was examined.
Results Of 70 patients enrolled in the parent trial, core biopsies samples with sufficient RNA for gene analyses were available from
45 patients; 9 (20%) had inflammatory breast cancer (IBC). Six (14%) patients achieved a pCR. Twenty-two of the 274 candidate
genes assessed correlated with pCR (p < 0.05). Genes correlating with pCR could be grouped into three large clusters: angiogenesis-related genes, proliferation
related genes, and invasion-related genes. Expression of estrogen receptor (ER)-related genes and Recurrence Score did not
correlate with pCR. In an exploratory analysis we compared gene expression in IBC to non-inflammatory breast cancer; twenty-four
(9%) of the genes were differentially expressed (p < 0.05), 5 were upregulated and 19 were downregulated in IBC.
Conclusion Gene expression analysis on core biopsy samples is feasible and identifies candidate genes that correlate with pCR to primary
chemotherapy. Gene expression in IBC differs significantly from noninflammatory breast cancer. 相似文献
7.
J S Ulmer A Herzka K J Toy D L Baker A H Dodge D Sinicropi S Shak R A Lazarus 《Proceedings of the National Academy of Sciences of the United States of America》1996,93(16):8225-8229
Human deoxyribonuclease I (DNase I), an enzyme recently approved for treatment of cystic fibrosis (CF), has been engineered to create two classes of mutants: actin-resistant variants, which still catalyze DNA hydrolysis but are no longer inhibited by globular actin (G-actin) and active site variants, which no longer catalyze DNA hydrolysis but still bind G-actin. Actin-resistant variants with the least affinity for actin, as measured by an actin binding ELISA and actin inhibition of [33P] DNA hydrolysis, resulted from the introduction of charged, aliphatic, or aromatic residues at Ala-114 or charged residues on the central hydrophobic actin binding interface at Tyr-65 or Val-67. In CF sputum, the actin-resistant variants D53R, Y65A, Y65R, or V67K were 10-to 50-fold more potent than wild type in reducing viscoelasticity as determined in sputum compaction assays. The reduced viscoelasticity correlated with reduced DNA length as measured by pulsed-field gel electrophoresis. In contrast, the active site variants H252A or H134A had no effect on altering either viscoelasticity or DNA length in CF sputum. The data from both the active site and actin-resistant variants demonstrate that the reduction of viscoelasticity by DNase I results from DNA hydrolysis and not from depolymerization of filamentous actin (F-actin). The increased potency of the actin-resistant variants indicates that G-actin is a significant inhibitor of DNase I in CF sputum. These results further suggest that actin-resistant DNase I variants may have improved efficacy in CF patients. 相似文献
8.
Bethanechol or cimetidine in the treatment of symptomatic reflux esophagitis: a double-blind control study 总被引:1,自引:0,他引:1
We conducted a double-blind study to compare the effectiveness of oral bethanechol chloride or cimetidine in treating reflux esophagitis to evaluate the drugs' effects on the symptoms of esophagitis and its verification by endoscopy. Forty-three patients were treated with either 300 mg of cimetidine or 25 mg of bethanechol chloride, each administered four times a day for six weeks. In addition to this drug treatment, the patients all received conventional medical therapy. Patients who were treated with either of the two drugs experienced a decrease in symptoms and less severe endoscopic lesions. While cimetidine treatment resulted in complete endoscopic healing in 15 of 22 patients, bethanechol treatment resulted in the same healing in 11 of 21 patients. During therapy, neither endoscopic lesions or symptoms worsened. Our study indicated that either cimetidine or bethanechol is an effective drug in treating reflux esophagitis. The effects of the two drugs can be favorably compared. 相似文献
9.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients 总被引:3,自引:0,他引:3
下载免费PDF全文
![点击此处可从《Breast cancer research : BCR》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Habel LA Shak S Jacobs MK Capra A Alexander C Pho M Baker J Walker M Watson D Hackett J Blick NT Greenberg D Fehrenbacher L Langholz B Quesenberry CP 《Breast cancer research : BCR》2006,8(3):R25-15
Introduction
The Oncotype DX assay was recently reported to predict risk for distant recurrence among a clinical trial population of tamoxifen-treated patients with lymph node-negative, estrogen receptor (ER)-positive breast cancer. To confirm and extend these findings, we evaluated the performance of this 21-gene assay among node-negative patients from a community hospital setting.Methods
A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 and not treated with adjuvant chemotherapy. Cases (n = 220) were patients who died from breast cancer. Controls (n = 570) were breast cancer patients who were individually matched to cases with respect to age, race, adjuvant tamoxifen, medical facility and diagnosis year, and were alive at the date of death of their matched case. Using an RT-PCR assay, archived tumor tissues were analyzed for expression levels of 16 cancer-related and five reference genes, and a summary risk score (the Recurrence Score) was calculated for each patient. Conditional logistic regression methods were used to estimate the association between risk of breast cancer death and Recurrence Score.Results
After adjusting for tumor size and grade, the Recurrence Score was associated with risk of breast cancer death in ER-positive, tamoxifen-treated and -untreated patients (P = 0.003 and P = 0.03, respectively). At 10 years, the risks for breast cancer death in ER-positive, tamoxifen-treated patients were 2.8% (95% confidence interval [CI] 1.7–3.9%), 10.7% (95% CI 6.3–14.9%), and 15.5% (95% CI 7.6–22.8%) for those in the low, intermediate and high risk Recurrence Score groups, respectively. They were 6.2% (95% CI 4.5–7.9%), 17.8% (95% CI 11.8–23.3%), and 19.9% (95% CI 14.2–25.2%) for ER-positive patients not treated with tamoxifen. In both the tamoxifen-treated and -untreated groups, approximately 50% of patients had low risk Recurrence Score values.Conclusion
In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients. 相似文献10.
Cenamps' highly talented and commercially experienced team work closely with business leaders to stimulate and manage market-led innovation, enabling businesses to develop new products and services as well as strengthen the regional economic foundation, R&D capabilities and performance. Cenamps achieves this by establishing new state-of-the-art R&D facilities and applied research projects for developing new technologies that will yield significant societal, economic and commercial benefits. 相似文献